Search

Your search keyword '"BRCA genes"' showing total 220 results

Search Constraints

Start Over You searched for: Descriptor "BRCA genes" Remove constraint Descriptor: "BRCA genes" Journal gynecologic oncology Remove constraint Journal: gynecologic oncology
220 results on '"BRCA genes"'

Search Results

1. Incidence of endometrial cancer in BRCA mutation carriers.

2. Occult residual ovarian tissue at the time of minimally invasive risk reducing surgery in women with BRCA mutations.

3. Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over.

4. Clinical characteristics and survival outcome of early-stage, high-grade, serous tubo-ovarian carcinoma according to BRCA mutational status.

5. Concordance between an FDA-approved companion diagnostic and an alternative assay kit for assessing homologous recombination deficiency in ovarian cancer.

6. Distribution and prognostic role of BRCA status in elderly ovarian cancer patients.

7. Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032).

8. Pathologic response to neoadjuvant chemotherapy in ovarian cancer and its association with outcome: A surrogate marker of survival.

9. Partner and localizer of BRCA2 (PALB2) pathogenic variants and ovarian cancer: A systematic review and meta-analysis.

10. A putative role for ALDH inhibitors and chemoprevention of BRCA-mutation-driven tumors.

11. Germline drivers of gynecologic carcinosarcomas.

12. Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial.

20. Financial toxicity in BRCA1 and BRCA2 carriers.

21. Missed opportunities in the real-world genetic testing in BRCA gene variant carriers with cancers meeting NCCN criteria.

22. Beyond BRCA: Patterns of risk-reducing surgery for non-BRCA, homologous recombination repair pathway gene variant carriers.

23. Validation of the KELIM score as a predictor of response to neoadjuvant treatment in patients with advanced high grade serous ovarian cancer.

24. DNA methylation of the immediate upstream region of BRCA1 major transcription start sites is an independent favorable prognostic factor in patients with high-grade serous ovarian cancer.

25. Management of ovarian and breast cancer risk in non-BRCA HBOC pathogenic variant carriers in a large California health care system.

26. Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.

27. Germline BRCA mutation carriers are more likely to undergo cytoreductive surgery for relapsed, platinum sensitive, ovarian cancer.

28. Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.

29. Germline BRCA variants, lifestyle and ovarian cancer survival.

33. Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.

34. Increased co-expression of MEST and BRCA1 is associated with worse prognosis and immune infiltration in ovarian cancer.

35. Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer – an ancillary data analysis of the VELIA trial.

36. Clinical outcomes of BRCA1/2 pathogenic variants in ovarian cancer cluster region in patients with primary peritoneal, epithelial ovarian, and fallopian tube cancer.

37. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.

38. Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?

39. Breast cancer surveillance following ovarian cancer in BRCA mutation carriers.

40. Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.

41. Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial.

42. Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.

43. Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer.

44. Ovarian cancer surveillance in the clinical follow up of women with known BRCA1 or BRCA2 pathogenic variants in a large health care system.

45. The preventive effect of breastfeeding against ovarian cancer in BRCA1 and BRCA2 mutation carriers: A systematic review and meta-analysis.

46. Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial.

47. The correlation between BRCA status and surgical cytoreduction in high-grade serous ovarian carcinoma.

48. Risk of cardiovascular disease among women carrying BRCA mutations after risk-reducing bilateral salpingo-oophorectomy: A population-based study.

49. Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational study.

50. Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial.

Catalog

Books, media, physical & digital resources